Rapid Readouts

1 expert is featured in this series.

Martin Voss, MD, reviews results from the phase 3 LITESPARK-011 trial presented at the 2026 ASCO Genitourinary Cancers Symposium, highlighting the progression-free survival benefit and safety profile of belzutifan plus lenvatinib compared with cabozantinib in patients with previously treated metastatic clear cell renal cell carcinoma.

1 expert is featured in this series.

This rapid readout highlights results from a global Phase III trial evaluating giredestrant as adjuvant therapy for estrogen receptor–positive, HER2-negative early breast cancer. The study demonstrated a clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy, with a favorable and comparable safety profile.

1 expert is featured in this series.

This video presents an updated analysis from the BENEFIT (IFM 20205) study, led by Professor Xavier Leleu, focusing on sustained measurable residual disease (MRD) negativity in patients with newly diagnosed multiple myeloma. Following the primary results published in Nature Medicine in 2024, this update examines MRD negativity over time using next-generation sequencing at 12, 18, and 24 months after treatment initiation. The discussion emphasizes that sustained MRD negativity—rather than a single timepoint or complete response rate—is the most clinically meaningful endpoint. Results show that quadruplet-based regimens achieve higher and more durable MRD negativity compared with triplet-based therapies. The video also explores outcomes in key biological subgroups, including patients with t(11;14) translocation, who demonstrate slower and lower rates of MRD negativity. Overall, the findings support the growing role of sustained MRD negativity as a critical endpoint to guide long-term treatment strategies in multiple myeloma.

Four-year follow-up results from the Phase 3 CheckMate 9DW trial show that nivolumab plus ipilimumab continues to provide sustained overall survival and durable response benefits versus lenvatinib or sorafenib as first-line therapy for unresectable hepatocellular carcinoma. The combination demonstrated higher long-term survival rates and a higher complete response rate, with no new safety signals reported.

In this real-world retrospective study of patients with CLL/SLL treated at UCSF, outcomes with next-generation BTK inhibitors zanubrutinib and acalabrutinib were compared using adjusted analyses of time to next treatment and overall survival. Despite patients receiving zanubrutinib having more high-risk features and comorbidities, zanubrutinib was associated with a lower risk of starting subsequent therapy and a trend toward improved survival compared with acalabrutinib.

The RRO highlights that isatuximab combined with RVd as induction therapy produced deep and rapid responses in transplant-eligible patients with newly diagnosed multiple myeloma. The regimen was generally well tolerated with a favorable safety profile, and early molecular responses were observed in a meaningful proportion of patients.

1 expert is featured in this series.

Using data from the ALPINE trial, this analysis demonstrates that worsening patient-reported symptoms, particularly fatigue, insomnia, and nausea/vomiting, is significantly associated with increased risk of disease progression in patients with relapsed/refractory CLL/SLL.